A antigen, 246

*A phagocytophilum*

agent survival in, 301

seroprevalence of, 299

transfusion transmission of, 299--300

ABO blood group system, 217--218

Accuracy, definition of, 82

Acetylcholinesterase, 208, 217

Acridine orange, 13

Adenosine diphosphate ribosyltransferase, 217

Adhesion molecule, 215

classification of, 208

ADP ribosyl transferase-4, 208

Advisory Committee on Blood Safety and Availability, 8

Africa, human T-cell lymphotropic virus I-II prevalence in, 49

Alloantibodies

of cats, 118, 119

induced canine, 121--122

natural canine, 121

Allogeneic blood, autologous *v*, economic evaluation of, 137

Allogeneic blood transfusion-related immunomodulation effect, 267--268, 273--274

Alloimmunization, prevention of, 252

Amicus Dual, 262, 263, 264

Amicus separator, 259

Amicus Single, 262, 263, 264

Amotosalen HCL, plus ultraviolet A, 19--20

Analysis, meta-, 271--272

components of, 271

*Anaplasma phagocytophilum*, 295

Antibiotic lableling, fluorescent, in bacterial detection system, 15--16

Antibiotic probe, 13

Antibody(ies)

human polyclonal, 203

monoclonal, 204

Antigen(s)

blood cell, construction of, 248

carbohydrate, 206

human platelet, 203

identified tumor-associated, 192

platelet, 203, 219--222

red blood cell, 203, 207--219

shared tumor, 193

Anti-Nak antibody, 222

Aquaporin-1-channel-forming integral protein, 208, 212

Aquaporin-3, 208, 212

Asia, human T-cell lymphotropic virus I-II prevalence in, 49--51

Autoantibodies

canine, 122

feline, 118--119

Autologous blood, allogeneic blood *v*, economic evaluation of, 137

B antigen, 246

*B divergens*, 295

seroprevalence of, 299

transfusion transmission of, 299--300

*B microti*

agent survival in, 301

seroprevalence of, 299

transfusion transmission of, 299--300

*Babesia microti*, 295

Babesiosis

diagnosis of, 297

seroprevalence of, 298--299

symptoms of, 296

Bacterial culture system, automated, 13--16

Bacterial detection system, 13

dielectrophoretic method in, 16

DNA or RNA-based, 13, 15

endotoxin-based, 16

fluorescent antibiotic labeling in, 15--16

Pall pO;i2 method of, 13, 14--15

peptidoglycan component detection in, 16

stained sample examination in, 16

storage metabolic parameter changes and, 15

Band 3-anion exchanger-1 transporter, 208, 210, 211--212

Basal cell adhesion molecule, 208, 215

Basigin, 216

Battery, definition of, 179

Bg antigen, 216

Biological product deviation, 38, 42

Biomedical Excellence for Safer Transfusion Working Party, 25--26

Birds, blood groups of, 123--124

Bleeding

major, 163

minor, 162

risk of, platelet count and, 159

in solid tumor patients, 165

Blood

donor, initial aliquot removal of, 17

escalating cost of, 1-2

sickle homoglobin, rheology of, 170

solvent-detergent treated, 6

in surgery study, 285--286

Blood bank factory, future, 254

Blood component(s)

follow-up of, in recall, 42

managing recall of, 40--41

reducing recall of, 43

Blood donor(s)

attitudes of, and variant Creutzfeldt-Jakob disease testing, 87--88

behavior of, factors influencing, 280--281

deferral rates of, 282

risk factor-based management of, 301--302

screening of, 16--17

seroconversion of, 43

Blood filter(s), 170--171

failure of, 171--173

Sepacell RS-2002, 171

sickle trait and, 174--175

Blood group

avian, 123--124

canine, 119--123

feline, 117--118

ferret, 123

human *v* canine, 121

Blood group antigen, canine, 122--123

Blood product(s)

benchmarks for use of, 285--286

cellular, leukoreduction of, 169--170

during storage, 283--285

Jehovah's Witnesses' beliefs regarding, 108--111

loss of, 281--283

manipulation of, 303

monitoring use of, 285

pathogen elimination in, cost-effectiveness of, 138

production of, regulatory requirements in, 279

professional education regarding, 97--99

transfusion-related acute lung injury due to, 185, 186

triggers for, 286--287

usage guidelines for, 97

Blood Products Advisory Committee, 8

Blood screening, 302--303

cost of, 2-3

Blood separation, 258--259

Blood transfusion

alternative strategies to, 111--113

alternatives to, demand for, 106

auditing of, 97--99

autologous, 101

British Committee for Standards in Haematology guidelines for, 98--99

computerized interventions for, 101--102

computerized regular timely feedback of, 101--102

cost issues regarding, 112--113

cost-effective interventions in, 136--138

decision-making for, 267

diseases transmitted in, risk of, 182

during war and peace, 288

economic evaluation in, 129

fatality due to, 185

future in, 288--289

guidelines for, 94--95

hemoglobin concentration and, 286

improvement interventions for, 99--101

indications for, 95--97

informed consent for, 181--182

Jehovah's Witnesses' beliefs regarding, 107--111

major surgery without, 111--113

minors and, 108--110

policy for, 94--95

product ordering for, 96

professional education regarding, 112

reaction to, risks of, 181

refusing, 287--288

risk factor-based donor management in, 301--302

safety adaptations for, 128

safety intervention cost-benefit in, 131--136

safety intervention cost-effectiveness in, 132--135

safety intervention cost-utility in, 133--135

safety issues regarding, 113

tick-borne infection transmitted by, 293--294

of variant Creutzfeldt-Jakob disease, 89

Bovine spongiform encephalopathy, 76

emergence of, 177

epidemiology of, 74

in Europe, 74

geographical risk of, 75

global epidemic of, 75

public health implications of, 75--76

in United Kingdom, 74

British Committee for Standards in Haematology, published guidelines of, 98

BS 6002, 33

C3-C4, 218

C4b-C4a, 208

C807T polymorphism, 220

C:T ratio, 96--97

Canada, leukoreduction in, 27, 28, 29, 31

Cancer vaccine, clinical trials of, 194--196

Canine blood groups, 121

Canine erythrocyte antigen, 120

Carbohydrate antigen, 206

Carbohydrate transferases, classification of, 208

Carribean basin, human T-cell lymphotropic virus I-II prevalence in, 52--53

Cartwright blood group system, 217

Cat(s)

alloantibodies of, 118, 119

autoantibodies of, 118--119

blood group antigens of, 119

blood groups of, 117--118

blood types of, geographic distribution of, 118

bloot type B frequencies in, 118

CD36, 222

CD44, 215

CD99, 216

CD108, 208

CD109, 222

CD147, 216

CDw108, 216

Center for Biologics Evaluation and Research, 185

Channel molecule, classification of, 208, 210

Chido-Rogers blood group systems, 218

Chronic wasting disease, 76

Coagulation, leukoreduction failure and, 172

Colorado tick fever virus, 295--297

agent survival in, 301

diagnosis of, 298

Colton blood group system, 212

Complement receptor 1, 208, 214

Complementary DNA expression libraries, 205

Confidentiality, and variant Creutzfeldt-Jakob disease testing, 86

Conformance, calculation of, 31--34

Cost

of allogeneic versus autologous blood, 137

in blood transfusion, 112--113

of blood transfusion safety interventions, 129

Cost index, 1

Cost-benefit evaluation, of blood transfusion safety interventions, 131

Cost-effectiveness evaluation

of blood transfusion safety interventions, 132--135

of donor blood pathogen elimination, 138

of transfusion medicine interventions, 136--138

Cost-utility evaluation, of blood transfusion safety interventions, 133--135

Coulter counter analysis, 265

Creutzfeldt-Jakob disease, 76

classic, 177

classic *v* variant, 178--179

FDA guidance regarding, 39

variant, *see* Variant Creutzfeldt-Jakob disease

Creutzfeldt-Jakob disease testing, patient care following, 88

Cromer blood group system, 214

Cryoprecipitate-reduced plasma, transfusion-related acute lung injury due to, 186

Crystal structure, 205--206

CS-3000 Double, 262, 263, 264

CS-3000 Single, 262, 263, 264

DEA 1-8, canine, 120--121

Decay accelerating factor, 208, 214

Dendritic cell

identification of, 191

molecular biology of, 191--192

sensitization of, 192--194

Dendritic cell-based immunotherapy

clinical trials of, 194--196

product preparation for, 196--198

quality assurance in, 198--199

rationale for, 189--191

Diagnosis-related groups, Medicare reimbursement and, 3-4

Dielectrophoresis, in bacterial detection system, 13, 16

DNA or RNA-based bacterial detection system, 13, 15

DNA-RNA chemoluminescence, 13

Dog, blood groups of, 119--120

Dombrock blood group system, 217

Donor, blood, *see* Blood donor(s)

Duffy glycoprotein, 213--214

*Ehrlichia chaffeensis*, 295

agent survival in, 301

Ehrlichoiosis

diagnosis of, 297

symptoms of, 296

Emergency patient(s), blood transfusion and, 111--112

Endotoxin, in bacterial detection system, 13, 16

England, leukoreduction in, 27--32

Enzymatic conversion, 254

Enzyme, expressing red blood cell antigens, 208

Enzyme-linked immunoassay, 13, 16

Epifluorescence microscopy, 13, 16

ERMAP, 208

Erythrocyte differentiation-related factor messenger RNA, 84--85

Erythrocyte membrane-associated protein, 216--217

Europe

bovine spongiform encephalopathy in, 74

human T-cell lymphotropic virus I-II prevalence in, 51--52

Evidence-based medicine

definition of, 268--269

evidence hierarchy for, 269--270

Evidence hierarchy, 269--270

Fatal familial insomnia, 76

FDA

blood memos of, 37

guidance of, 39

regulatory requirements of, 38--40

Febrile reaction, risk of, in transfusion, 181

Feline spongiform encephalopathy, 76

Fenwal instruments, 258

Ferret, blood groups of, 123

Filtration time, leukoreduction failure and, 172--173

Flow cytometry, for leukocyte counting, 29

Fluorescent antibiotic labeling, in bacterial detection system, 15--16

France, leukoreduction in, 27, 28, 30, 32

Fresh frozen plasma, transfusion-related acute lung injury due to, 185, 186

Fucosyltransferase, 248

Fy glycoprotein, 208

Galactosyltransferase, 248

Gamma-irradiation, 18--19

Gelling, of blood, 170

Genomics, definition of, 84

Germany, leukoreduction in, 27, 28, 30, 32--33

Gerstmann-Straussler-Scheinker disease, 76

GIL blood group system, 212

Globosidases, 218

Glycophorin A, 203, 207--209

Glycophorin B, 207--209

Glycophorin C, 208, 209--210

Glycophorin D, 208, 209--210

Glycoprotein Ia, 220

Glycoprotein Ib alpha, 221

Glycoprotein Ib beta, 221

Glycoprotein IIIa, 220--221

Glycoprotein IV, 222

Glycoprotein V, 221--222

Glycosylphosphatidylinositol anchor, 205, 207

Glycosyltransferases, 217--218

Gobosidases, 208

GPI-anchored protein, 222

Gram stain, in bacterial detection system, 13, 16

Group A red blood cells, to group O, 247--249

Group B red blood cells, to group O, 246--247

H antigen, 246

H blood group system, 217--218

Hematopoietic stem cell, quality control for, 198--199

Hemolytic reaction, risk of, in transfusion, 181

Hemorrhage, platelet count and, 163

Hermes antigen, 208

Hospital, operating margin of, 4

Hospital Liaison Committees, 110--111

Hospital transfusion committee

development of, 93--94

functions of, 94--99

membership of, 94

HPA-1 platelet antigen system, 220--221

HPA-15w system, 222

HPA-2 platelet antigen system, 221

HPA-4 platelet antigen system, 220--221

HPA-5 system, 220

HTVL-I-associated myelopathy-tropical spastic paraparesis, 47--48

Human blood groups, 121

Human platelet antigen system, 203

Human polyclonal antibodies, 203

Human T-cell lymphotropic virus

confirmatory tests for, 48--49

screening for, 48

Human T-cell lymphotropic virus I-II, prevalence of, 49--53

Human T-cell lymphotropic virus type I, transmission of, 46--47

Human T-cell lymphotropic virus type II, transmission of, 46--47

Hypotonic shock response, 61

I blood group system, 217--218

I domain, 220

Immunofluorescence assay, in bacterial detection system, 13, 16

Index

of hospital costs, 1

market basket, 1-3

producer price, 3

Indian blood group system, 215

Informed consent

for blood transfusion, 181--182

overview of, 179--180

risk denial and, 180--181

in variant Creutzfeldt-Jakob disease testing, 85--86

Integrin adhesion molecule, classification of, 209

Integrin alpha-2, 220

Integrin beta-3, 220--221

Intercellular adhesion molecule-4, 208

INTERCEPT blood system, for platelets, 19

International Society for Blood Transfusion, 206--207

Italy, leukoreduction in, 27, 28, 30, 33

Jehovah's Witnesses, beliefs of

regarding blood transfusion, 107--111

regarding medical treatment, 106--107

JMH blood group, 216

Kell blood group system, 217

Kell glycoprotein, 208

Kidd glycoprotein, 208, 213

Knops blood group system, 214

Kolmogorov-Smirnov nonparametric population comparison, 31

Kunicki method, 63

Kuru, 76

L-carnitine, 18

effect of, on irradiated red cells, 59

molecular structure of, 59

photochemically-treated red cells and, 60

platelet storage and, 61--64

red cell storage and, 58--61

red cell volume and, 60, 61

Laboratory Accreditation Program of the College of American Pathologists, 40

Laboratory testing, accuracy of, 82

Latex particle agglutination, 13

Le blood group system, 217--218

Leucine-rich receptor molecule, 209

Leukocyte counting, 28--30

Leukocyte reduction, 254

Leukofiltration, failure of, 171--173

Leukoreduction, 273--274

of cellular blood products, 169--170

cost of, 2-3

countries monitoring, 31--34

discard limits for, 27

filtration performance issues and, 30

monitoring of, 31--34

review of, 34--35

sampling for, 27--28

of sickle hemoglobin blood, 170--171

specifications for, 26--27

tick-borne infection and, 303

universal, *see* Universal leukoreduction

upper specified limit for, 27

Leukoreduction filter, in variant Creutzfeldt-Jakob disease transmission, 89--90

Leukotrap filter, Pall, 90

Lutheran blood group system, 215

Lutheran glycoprotein, 208

LW blood group system, 215--216

LW glycoprotein, 208

Lyme disease, 294

Market basket index, 1-3

Market withdrawal, FDA definition of, 37

Material risk, definition of, 179

Maximum Surgical Blood Order Schedule, 96, 100

Medical directive, 109

Medicare reimbursement

diagnosis-related groups and, 3-4

for blood, 1-2

lag of, 6-7

prospective, 4

MER2, 208, 218--219

Meta-analysis, 271--272

Metalloproteinase, 217

Methionine, 77

screening for, 89

Millipore filter, 170

Minors

blood transfusions and, 108--110

mature, 110

Monoclonal antibodies, 204

Morphology score, 63

Nageotte chamber counting, 28--29

National Blood Services, 283

Negative predictive value, definition of, 82

Negligence

definition of, 179

variant Creutzfeldt-Jakob disease testing and, 86--87

Neonate(s), red blood cell transfusion to, 173--174

Netherlands, leukoreduction in, 27,28, 30, 33

Neurothelin, 208, 216

North America, human T-cell lymphotropic virus I-II prevalence in, 52

Nucleic acid testing, 136

cost of, 2

Null phenotype, 205

Odds ratio, 271

OK blood group system, 216

Orphan molecule, 218

Oxygenation, leukoreduction failure and, 173

P1 blood group system, 218

Pall bacterial detection system, 13--15

Paraglobosidases, 218

Pathogen inactivation, 254

methodology for, 18--20

tick-borne infection and, 303

PEG conjugates, 249

PEG-red blood cells, 245, 247, 249--254

antigenic, 253--254

chemistry of, 251

function of, 251

immunogenic, 253--254

in vivo survival of, 252--253

linear, 249, 250--251

monofunctional, 252

morphology of, 251

multifunctional, 252

preparing, 250

second-generation, 251--252

serological problems with, 250--251

Phosphatidylserine, 63, 64

Plasma membrane protein, classification of, 206--207

Platelet(s)

apheresis-derived, 18

bacterial contamination of, 11--12, 16--17

counting of, 259

microcytic, 265

optimizing transfusion indications for, 18

pretransfusion bacterial detection and, 12--16

storage of, and L-carnitine, 61--64

storage temperature for, 17

storage time for, 17

stored apheresis, and L-carnitine, 64

universal leukoreduction and, 18

Platelet antigen system, 203, 219--222

Platelet count

bleeding risk and, 159

bleeding risk studies and, 162--163

hemorrhage and, in nontransfused thrombocytopenic patients, 154--155

major bleeding and, 163

minor bleeding and, 162

platelet survival and, 154

Platelet GPIa-IIa complex, 220

Platelet swirling pattern, 13

Platelet transfusion, 96

in active bleeding, 156--158

5, 10, or 20 × 103 microns per liter triggers of, 161

at 5 × 103 microns per liter, 158--160

hemostasis and, 155--156

prophylactic, trigger trials for, 158

prophylactic versus therapeutic, 156, 157

prophylactic versus therapeutic trials of, 158

protocol for, 159

requirements for, 157

solid tumor patients and, 164--165

stem-cell transplant patients and, 163--164

stool blood loss and, 161

thrombocytopenia duration and, 161

transfusion-related acute lung injury due to, 186

trigger for, 153--154

Platelet transfusion-associated septic risk, reduction of, 12

Plateletpheresis

collections of, 260

improved technology for, 257

Polymerase chain reaction, 13

Portugal, leukoreduction in, 27, 28

Positive predictive value, definition of, 82

P-Pk blood group system, 218

Prion, definition of, 177--178

Prion protein, 178

screening for, 84--85

Prion protein gene, human, 77

Process performance, 31--32

Producer price index, 3

Proteomics, definition of, 84

Quality control, in dendritic cell-based immunotherapy products, 198--199

*R rickettsii*, agent survival in, 301

Randomized controlled trial(s)

in evidence hierarchy, 270--271

meta-analysis of, 271

systemic reviews of, 271--272

RAPH blood group system, 218--219

Reagent strip, 13

Recall

of blood components, 36--38

FDA definition of, 37

managing blood, 40--41

reducing, of blood components, 43

Receptor, expressing red blood cell antigens, 208

Red blood cell

group A, to group O, 247--249

group B, to group O, 246--247

irradiated, and L-carnitine, 59

pegylation, 249--254

photochemically-treated, and L-carnitine, 60

stealth, 254

storage of, and L-carnitine, 58--61

universal donor, 245

volume of, and L-carnitine, 60, 61

Red blood cell antigen, structural molecules of, 207

Red blood cell antigen system, 203, 207--219

Red blood cell leukoreduction, cost reimbursement and, 2

Red blood cell transfusion

to neonates, 173--174

stool blood loss and, 161

transfusion-related acute lung injury due to, 186

Rh, classification of, 207--209

Rh-associated glycoprotein, 210

Rh complex, 210

Rh null phenotype, 205

Rh polypeptides, 210--211

Riboflavin, plus ultraviolet A, 19

Ribosomal RNA probe, 13

*Rickettsia rickettsii*, 295--296

Risk, in blood transfusion, and informed consent, 181--182

Rocky Mountain Spotted Fever

diagnosis of, 297--298

symptoms of, 296--297

Safe and good use of blood in surgery study, 112

Scianna-Radin blood group system, 216--217

Scientific evidence hierarchy, 269--270

Scotland, leukoreduction in, 27, 28

Scrapie, 76

Screening, for Human T-cell lymphotropic virus, 48

Screening test

accuracy of, 82--83

for bovine spongiform encephalopathy, 84--85

definition of, 83

efficacy of, 83--84

predictive value of, 84

specificity of, 83

for variant Creutzfeldt-Jakob disease, 84--85

Se blood group system, 217--218

Sensitivity, definition of, 82

Sepacell filter, 170--171

Sepacell RS-2000 filter, 171

Severe acute respiratory syndrome, FDA guidance regarding, 39

Sickle hemoglobin, 168--169

Sickle hemoglobin blood

early filtration experiments with, 170--171

magnitude of, 170

rheology of, 170

Sickle trait

filtration failure and, 174

filtration time and, 174--175

Sickling, of blood, 170

Smallpox vaccination, FDA guidance regarding, 39

Sodium dodecylsulfate-polyacyrlamide gel electrophoresis, 204--205

Solid tumor patient

bleeding in, 165

platelet transfusion and, 164--165

thrombocytopenia in, 165

Solvent-detergent treated plasma component, 6

South America, human T-cell lymphotropic virus I-II prevalence in, 52--53

Specificity, definition of, 82

Spectra Dual, 262, 263, 264

Spectra separator, 258--259

Spectra Single, 262, 263, 264

Split rate, 260, 263

collection yield and, 261, 262

distribution yield and, 261, 262

Spongiform encephalopathies, transmissible, 76

SPSS analysis, 259

Stability monitoring, 32

Standard of care, variant Creutzfeldt-Jakob disease testing and, 86

Standards of the American Association of Blood Banks, 40

Stem-cell transplant patients, platelet transfusion in, 163--164

Structural molecule, classification of, 208

Summary effect, 271

Surgery, without blood transfusion, 111--113

Surgical blood order equation, 100

T-cell stimulation, dendritic cells and, 191--192

Temperature, leukoreduction failure and, 171--172

Therapeutic intervention efficacy, in evidence hierarchy, 271

Therapeutic privilege, definition of, 179--180

Thrombocytopenia

duration of, and platelet transfusion, 161

in solid tumor patients, 165

Thrombocytopenic patient

fecal blood loss in, 155

hemorrhage in, and platelet count, 154--155

Tick-borne encephalitis, diagnosis of, 298

Tick-borne encephalitis virus, 295--297

Transferase, carbohydrate, 208

Transfusion, decision-making for, 267

Transfusion medicine, evidence-based policy decisions in, 272--274

Transfusion Medicine Epidemiology Review, 78

Transfusion reaction, risk of, 181

Transfusion-related acute lung injury

admitting diagnosis in, 186

fatality age and, 185

fatality gender and, 185, 186

incidence of, 184--185

symptoms of, 185

Transfusion requirements, in critical care study, 287

Transfusion trigger, reduction of, 18

Transmissible mink encephalopathy, 76

Transmissible spongiform encephalopathies, 76

surveillance for, 89

transfusion studies in, 81

Transporter molecule, 210

TRIM effect, 267--268, 273--274

Tumor-associated antigen

classification of, 193

identified, 192

Ultraviolet A

amotosalen HCL plus, 19--20

riboflavin plus, 19

United Kingdom

bovine spongiform encephalopathy in, 74

variant Creutzfeldt-Jakob disease in, 78

North American disease testing and, 86

Universal donor red blood cells, 245

Universal leukoreduction, 2-3, 18

Urticaria, risk of, and transfusion, 181

Vaccination, cancer, clinical trials of, 194--196

Valine, 77

screening for, 89

Variant Creutzfeldt-Jakob disease

active surveillance for, 89

animal infectivity levels in, 80

animal studies of, 79

blood supply and, 177

case-control study of, 77

*v* classic, 178--179

etiology of, 76--77

fractionated products in, 81

human studies of, 79

immunocytochemical epidemiologic surveillance and, 77--78

incidence of, 76

intracranial animal studies of, 79--80

intravenous animal studies in, 80

leukofiltration and, 81

leukoreduction filter transmission of, 89--90

pathogenesis of, 76--77

risk absence for, 89

secondary, 78

testing for, legal aspects of, 85--87

in transfusion, 79

transfusion transmission of, 89

transmission of, impact of, 90

treatment of, 81

in United Kingdom, 78

Variant Creutzfeldt-Jakob disease testing

communicating implementation of, 90

communicating strategy for, 90

cost benefit of, 91

exploiting United Kingdom experience prior to, 90

false positives in, 90

geographic deferrals and, 90--91

impact of, on blood donation, 90

informed consent in, 85--86

issues regarding, 88

for risk factors, 89

validating, 88--89

Venepuncture site, disinfection of, 17

VLA protein, 220

WA-1, 295

agent survival in, 301

seroprevalence of, 299

transfusion transmission of, 299--300

Wales, leukoreduction in, 27, 28

West Nile virus, FDA guidance regarding, 39

White blood cell reduction, 254, 273--274

Xg blood group system, 216

Xga glycoprotein, 208

Xk glycoprotein, 208, 212
